This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
NK4 (Gene Therapy)
Kringle Pharma, Inc.
Drug Names(s): NK4 (Gene Therapy)
Kringle is developing NK4 as a gene and protein therapy.
NK4 is a competitive antagonist of the HGF/cMet interaction. It is composed an N-terminal hairpin domain and four K-domains from HGF. Thus, it contains the cMet receptor binding domain but lacks biological activity. That is, it displaces HGF binding to cMet receptor but does not activate the receptor.
NK4 (Gene Therapy) News
Pink Sheet India Proposes Safeguards For Gene Therapies
Additional information available to subscribers only: